tion; cell cycle Scaold and adapter proteins are attracting more and more interest due to the realization of their role in the regulation of numerous intracellular processes (Hunter, 2000) . The assessment of the true value of scaolding and adapter proteins in cellular regulation follows the progress in the in depth understanding of the complexity of events and cellular structures that mediate various physiological processes in the cell. Thus, this diverse family of proteins, which has been overlooked somehow as lacking catalytic activity, has lately gained a better deserved notice which pertains to various biological disciplines as apparent in the present review edition. The most studied example of a scaold protein is IRS-1, which was among the ®rst to be identi®ed and cooperates signals from various tyrosine kinase receptors to downstream eectors as Ras and PI-3 kinase. Contrary to tyrosine phosphorylation, where the importance of its ability to generate docking points for protein binding and mediate protein complex formation through scaold and adapter proteins like IRS-1, to its function, has been realized early on (Pawson and Nash, 2000; Pawson and Scott, 1997) , the same concept for serine threonine phosphorylation only recently started to draw attention (Barinaga, 1999; Kay et al., 2000; Yae and Cantley, 1999) . This recognition followed the discovery of proteins and protein domains that form a distinct family of scaold and adapter proteins that bind to serine/threonine phosphorylated residues within a speci®c context (Yae and Elia, 2001 ). This expanding family includes the members of the 14-3-3 proteins, components of the ubiquitin ligase complex such as FWD1 and Nedd4 and the DNA damage checkpoint protein kinase Rad53 (Figure 1 ). This review focuses on 14-3-3, being the ®rst one to be identi®ed from the above family and a central player in the phosphorylation-dependent regulation of diverse cellular processes.
14-3-3 proteins positively regulate several biological systems in dierent organisms e.g. cell cycle timing and cell cycle arrest in response to DNA damage, stress and mating pheromone in yeast (Ford et al., 1994; Roberts et al., 1997; Zeng et al., 1998) , photoreceptor development and learning in Drosophila (Broadie et al., 1997; Chang and Rubin, 1997; Kockel et al., 1997; Li et al., 1997; Skoulakis and Davis, 1996) and the Ras/Raf signaling pathway in various organisms. More than 60 dierent proteins have been reported to associate with 14-3-3 proteins in vivo (Chung et al., 1999; Finnie et al., 1999; Fu et al., 2000; Roberts, 2000; Skoulakis and Davis, 1998) . Among these are proteins involved in cell cycle control such as Cdc25 (Conklin et al., 1995; Peng et al., 1997) , Wee1 (Honda et al., 1997) , p53 (Waterman et al., 1998) , CDC2 (Chan et al., 1999) , CDK2 (Laronga et al., 2000) and the centrosome structure (Pietromonaco et al., 1996) , proteins involved in cellular signaling and stress response like Raf (Fantl et al., 1994; Freed et al., 1994; Fu et al., 1994; Irie et al., 1994) , IGF-I receptor (Craparo et al., 1997; Furlanetto et al., 1997) , IRS-1 (Craparo et al., 1997; Ogihara et al., 1997) , PI-3 kinase (Bonnefoy-Berard et al., 1995) , PKC (Aitken et al., 1995a) , Cbl (Liu et al., 1996) , Bcr (Reuther et al., 1994) , polyoma middle T antigen , MEKK-1 and 4 (Fanger et al., 1998 ), MLK2 (Nagata et al., 1998 , BAD (Zha et al., 1996) and ASK-1 (Zhang et al., 1999a) , transcription regulation such as FKHRL1 (Brunet et al., 1999) , DAF-16 (Cahill et al., 2001) , TAZ (Kanai et al., 2000) , TLX-2 (Tang et al., 1998) and histone deacetylase (Grozinger and Schreiber, 2000; Wang et al., 2000a) and cytoskeletal proteins like keratin K18 (Liao and Omary, 1996) and vimentin (Tzivion et al., 2000) .
14-3-3 binding has been shown to variably regulate its partners, ranging from positive to negative regulation via several dierent mechanisms described in detail in this review.
14-3-3 structure and target protein binding The 14-3-3 proteins are small acidic proteins with a molecular mass ranging from 27 to 32 kDa, with no detectable catalytic domain or function (Aitken et al., 1995c; Dubois et al., 1997a; Fu et al., 2000; Muslin and Xing, 2000; Shaw, 2000; Skoulakis and Davis, 1998) . There are seven identi®ed 14-3-3 isoforms in mammals which are highly conserved through evolution from the yeast to mammals (Rosenquist et al., 2000; Wang and Shakes, 1996) and interchangeable among species, as the mammalian and plant 14-3-3s can rescue yeast mutants devoid of 14-3-3. The 14-3-3 proteins are naturally dimeric and can form homo-or heterodimers with the other 14-3-3 isoforms . All the 14-3-3 proteins share a similar structure, composed of a dimerization region located at the amino-terminus and a target-protein-binding region. Crystal structure analysis and mutational studies demonstrated that the 14-3-3 target-binding region contains residues from both the amino-and carboxyterminal parts of the protein and revealed that 14-3-3 dimerization is mediated by a large interface composed of several regions within the amino-terminal part (Ichimura et al., 1995; Liu et al., 1995; Luo et al., 1995; Wang et al., 1998; Xiao et al., 1995; Zhang et al., 1997) . The initial studies indicated that the binding of 14-3-3 to its target protein requires phosphorylation of the target protein. This was the case for 14-3-3 binding to tryptophan and tyrosine hydroxylases (Furukawa et al., 1993; Ichimura et al., 1988) , Raf and Bcr (Michaud et al., 1995) . The phosphorylation dependent binding of 14-3-3 was demonstrated by the requirement of tryptophan hydroxylase phosphorylation for association with 14-3-3 (Furukawa et al., 1993) and later by the ability of substitution of speci®c phosphorylation sites of Raf e.g. Ser 259 and Ser 621 to Ala to inhibit Raf-14-3-3 association, as well as by the ability of Raf and Bcr dephosphorylation to inhibit in vitro 14-3-3 binding (Michaud et al., 1995) . These observations led Muslin et al. (1996) to a more speci®ed study to determine the requirements for 14-3-3 binding. Using synthetic phosphopeptides based on the Raf Ser 259 site, the authors identi®ed a speci®c motif required for association with 14-3-3 proteins; RSxpSxP, where pS represents phosphoserine and x any amino acid. By various substitutions of amino acids surrounding the phosphoserine it was determined that an arginine at position 74 or 73, serine at position 72 and a proline at position +2 were critical for the association. It was also shown that only phosphoserine at the right position allowed binding, while phosphorylation of the serine at position 72 did not contribute to binding. This work did not detect any preference to speci®c amino acids at other positions e.g. 75, 71, +1 or +3. Importantly, the 14-3-3-binding phosphopeptide is able to compete for 14-3-3 binding and dissociate preexisting Raf-14-3-3 complexes (Muslin et al., 1996; Tzivion et al., 1998) as well as most other 14-3-3-target protein complexes (Tzivion G and Avruch J, unpublished observation) . In complimentary studies, Yae et al. (1997) and Rittinger et al. (1999) expanded these results and using phosphopeptide libraries determined the existence of two preferred 14-3-3 binding motifs: RSxpSxP (mode 1) and RxxxpSxP (mode 2). Their results, however, implied some preference for aromatic or positively charged amino acid at position 71 (mode 1) or aromatic at position 72 and positive at position 71 (mode 2) and a preference for Leu, Glu, Ala or Met at position +1. These studies also resolved the crystal structures of 14-3-3 bound to phosphopeptides and demonstrated that the 14-3-3 dimer binds a single peptide in each groove independently and conclusively determined the regions in 14-3-3 crucial for target protein binding, con®rming the results obtained by genetic and biochemical studies of 14-3-3 mutants. The results of these and other studies are summarized in Figure 2 which shows 14-3-3 regions and residues involved in dimerization and target-protein binding. It is important to notice that although most of the 14-3-3 partners identi®ed to date contain either mode 1 or mode 2 motifs, several proteins that interact with 14-3-3 in a phosphorylation dependent manner do not contain either of these motifs e.g. IGF-I receptor (Furlanetto et al., 1997) , IRS-1 (Craparo et al., 1997; Ogihara et al., 1997) and Wee1 (Honda et al., 1997; Wang et al., 2000b) , indicating that some variations on the above motifs are tolerable. Moreover, 14-3-3 was found to bind several nonphosphorylated proteins such as exoenzyme S (Masters et al., 1999) and Cdc25B (Mils et al., 2000) and several nonphosphorylated peptides (Wang et al., 1999) . Interestingly, the 14-3-3 phosphopeptide-binding region also mediates the binding to the nonphosphorylated peptides and these bindings may be competed by each other (Wang et al., 1999) .
Signi®cance of 14-3-3 dimerization in target binding and regulation
The primary experiments have indicated that the 14-3-3 proteins are naturally dimeric and subsequently it has been demonstrated that they can form both homo-and hetero-dimers (Aitken et al., 1995c; Jones et al., 1995) . Resolution of the 14-3-3 crystal structure also pointed out the dimeric nature of the proteins and indicated that the dimerization interface is formed by interaction of helix A (3 ± 17) of one 14-3-3 with helixes C (39 ± 68) and D (75 ± 107) of the counter 14-3-3 monomer and vise versa (Fu et al., 2000; Liu et al., 1995; Xiao et al., 1995) . Con®rming results were obtained by Luo et al. (1995) who, using 14-3-3 fragmentation analysis con®ned the dimerization domain to amino acids 1 ± 139 and demonstrated that deletion of the amino terminal part of 14-3-3 (1 ± 79) prevents dimerization. A cognate work showed that even a smaller deletion e.g. 1 ± 32, suces to block 14-3-3 dimerization (Gu and Du, 1998) . Substitution of critical aminoacids in the predicted dimerization interface completely abolished 14-3-3 dimerization while no apparent change in the target protein Raf-1 binding was detected, pointing out crucial residues for dimerization (Tzivion et al., 1998) . Several monomeric forms of 14-3-3 tested for certain target protein binding did not reveal changes in binding capabilities, suggesting that dimerization does not aect target protein binding (Gu and Du, 1998; Ichimura et al., 1995 Ichimura et al., , 1997 Luo et al., 1995; Tzivion et al., 1998) . However, a more recent work indicates that 14-3-3 dimerization is required for binding to certain target proteins (Tzivion G and Avruch J, unpublished observation and Tzivion et al., 2000) . An explanation for these con¯icting ®ndings may be found in Yae et al. (1997) who demonstrated that having two 14-3-3 binding sites on a single polypeptide increases 14-3-3 binding anity by more than 30-fold. Thus, proteins having two low anity 14-3-3 binding sites (e.g. not matching the described preferred motifs) will bind to dimeric 14-3-3 but not to monomeric 14-3-3 forms, while proteins having a high anity site (matching the preferred motifs) will also be able to bind to monomeric 14-3-3. Supporting this hypothesis, it has been demonstrated that several 14-3-3 targets e.g. Wee1 (Honda et al., 1997) , keratin K18 (Ku et al., 1998) , Cbl (Liu et al., 1997) IGF-I receptor (Craparo et al., 1997) , IRS-1 (Ogihara et al., 1997) and DAF-16 (Cahill et al., 2001 ) which do not contain the identi®ed preferred motif, require the presence of more than one Figure 2 14-3-3 domains and residues involved in dimerization and target protein binding. Indicated are the 14-3-3 dimerization domain and mutations that abrogate 14-3-3 dimerization (red), regions and residues that form the target binding pocket (blue) and the location of the nuclear export sequence (NES; brown) phosphorylation site for stable 14-3-3 binding. The role of 14-3-3 dimerization extends however beyond target protein binding and has a profound role in the regulation of the target protein function. This concept has been demonstrated in the case of Raf regulation where both monomeric and dimeric forms of 14-3-3 bind Raf but only the dimeric form supports Raf kinase activity, probably by conferring a conformational change in Raf by binding to two sites simultaneously (Tzivion et al., 1998 (Tzivion et al., , 2000 . Accordingly, 14-3-3 ability to regulate the DNA binding of the transcription factor DAF-16 depended on 14-3-3 dimerization and on the presence of two 14-3-3 binding sites on DAF-16 (Cahill et al., 2001) . These results are forti®ed also by the ®nding that 14-3-3 mutations that disrupt target protein binding function as dominant negative forms, probably by sequestering endogenous 14-3-3 into dimer forms in which one monomer is capable of target binding and the other is not Xing et al., 2000; Zhang et al., 1999b) . Accordingly, a recent study that co-crystallized 14-3-3 with serotonin N-acetyltransferase (AANAT) points to a structure where a dimer 14-3-3 binds a single AANAT molecule phosphorylated at two sites and confers a conformational change that results in enhanced AANAT enzymatic activity (Obsil et al., 2001 ).
14-3-3 modes of action
Some ambiguity surrounds 14-3-3 function due to the many reports that attribute diverse properties to the 14-3-3 proteins, e.g. activator of tryptophan and tyrosine hydroxylases (Ichimura et al., 1988) , inhibitor of protein kinase C (Robinson et al., 1994) , activator of Raf-1 (Fantl et al., 1994; Freed et al., 1994; Irie et al., 1994) , inhibitor of PI-3 kinase (Bonnefoy-Berard et al., 1995; Kosaki et al., 1998) , regulator of DNA checkpoint (Ford et al., 1994; Peng et al., 1997) . All these distinct activities, however, result from a single 14-3-3 property, which is the ability to bind speci®c phosphoserine/threonine motifs on the target protein. Thus, the variability in 14-3-3 performance is not an intrinsic 14-3-3 trait but rather re¯ects a feature of the target protein.
The dierent 14-3-3 functions can be grouped into ®ve major modes of action: (i) 14-3-3 binding can alter the ability of the target protein to interact with other proteins. Examples of this scenario include Bad (Datta et al., 2000; Hsu et al., 1997; Zha et al., 1996) , Cbl , PI-3 kinase and IRS-1 (Kosaki et al., 1998) . In the case of BAD, 14-3-3 binding competes with Bcl2 binding, relieving Bcl2 for its antiapoptotic function and in the case of IRS-1 and PI-3 kinase, 14-3-3 binding to IRS-1 attenuates its ability to recruit and activate PI-3 kinase. (ii) 14-3-3 binding can modify the target protein localization : this function is achieved by two distinct mechanisms: I. 14-3-3 may facilitate nuclear export of its target protein via a nuclear export sequence present on its carboxyterminus (Lopez-Girona et al., 1999) . II. 14-3-3 can mask a nuclear import sequence on the target protein and reduce the rate of its nuclear import . Combined together, 14-3-3 binding has been demonstrated in several examples to cause its target's exclusion from the nucleus and its retention in the cytoplasm. Examples of this mode of regulation include the cell cycle protein phosphatase Cdc25C (Dalal et al., 1999; Kumagai and Dunphy, 1999) , the insulin regulated transcription factors FKHRL1 and DAF-16 (Brunet et al., 1999; Cahill et al., 2001) , telomerase (Seimiya et al., 2000) , PKU (Zhang et al., 1999b) and histone deacetylase (Grozinger and Schreiber, 2000) . (iii) 14-3-3 can bridge two proteins together, thus serving as a phosphorylation dependent scaold protein (Luo et al., 1996; Marshall, 1996; Xiao et al., 1995) . This function was demonstrated for Raf-Bcr (Braselmann and McCormick, 1995) , Raf-A20 (Vincenz and Dixit, 1996) and Raf-PKCz interactions (Van Der Hoeven et al., 2000) . (iv) 14-3-3 binding can alter the intrinsic catalytic activity of the target protein, inhibit or augment its function. Examples of this capacity include 14-3-3 ability to support Raf kinase activity and serve as a catalytic cofactor (Thorson et al., 1998; Tzivion et al., 1998) , enhance tryptophan and tyrosine hydroxylase kinase activities (Ichimura et al., 1988) , increase p53 DNA binding activity (Waterman et al., 1998) , inhibit ASK-1 kinase activity (Liu et al., 2001; Zhang et al., 1999a) , inhibit RGS activity (Benzing et al., 2000) and block DAF-16 DNA binding (Cahill et al., 2001) . (v) 14-3-3 binding can protect the target protein from other modi®cations such as dephosphorylation (Chen and Wagner, 1994; Chiang et al., 2001; Dent et al., 1995; Jelinek et al., 1996) and proteolysis (Cotelle et al., 2000; Weiner and Kaiser, 1999) .
As it appears, 14-3-3 binding, unlike ubiquitination for instance, serves more than just to mark the phosphorylated protein, and has an active and distinctive role in the further regulation and function of the target protein. In several cases 14-3-3 can exert more than one function in the regulation of a particular target. For example, it both maintains an inactive conformation of Raf in resting cells and enables engagement of the active conformation in stimulated cells (Tzivion et al., 1998) and in the case of DAF-16 it regulates both DAF-16 localization and its intrinsic DNA binding activity (Cahill et al., 2001) .
Regulation of 14-3-3
How are the 14-3-3 proteins being regulated? Are they regulated at all or is the regulation entirely at the level of the target protein phosphorylation/dephosphorylation? These questions are largely unresolved. Despite the large body of reports on 14-3-3 proteins, only a limited eort has been devoted to study the 14-3-3 proteins themselves. There are several reports which demonstrate that 14-3-3 proteins are being phosphory-lated (Aitken et al., 1995b; Dubois et al., 1997a) and two kinases were reported to phosphorylate 14-3-3 e.g. SDK1 (Megidish et al., 1995 (Megidish et al., , 1998 and Casein kinase I (Dubois et al., 1997b) . However, the role of these phosphorylations in the regulation of 14-3-3 function remains to be determined. Reports that describe variability in 14-3-3 expression portray an obscure picture; elevation in 14-3-3 expression has been correlated with neurodegenerative diseases (Hashiguchi et al., 2000; Lay®eld et al., 1996; Lee and Harrington, 1997; Muller et al., 2000; Zeidler, 2000) and cancer (Hermeking et al., 1997; Nakanishi et al., 1997; Shoji et al., 1994; Villaret et al., 2000) . However, suppression in 14-3-3 expression has also been related to cancer (Ferguson et al., 2000; Laronga et al., 2000; Suzuki et al., 2000; Vercoutter-Edouart et al., 2001 ) and the validity of elevated 14-3-3 expression in neurodegenerative disease detection has been questioned (Chapman et al., 2000; Green et al., 2001 ). 14-3-3 proteins seem to be variably localized (Perego and Berruti, 1997; Tien et al., 1999; van Zeijl et al., 2000) ; several reports demonstrate cytoplasmic localization (Dalal et al., 1999; Kumagai and Dunphy, 1999; Muslin and Xing, 2000) , others demonstrate colocalization with cytoskeletal (Garcia-Guzman et al., 1999; Ku et al., 1998; Nagata et al., 1998) and centrosome structures (Pietromonaco et al., 1996) and others describe 14-3-3 con®nement to the nucleus (Bihn et al., 1997; Pan et al., 1999; Tang et al., 1998; Todd et al., 1998) . This variability is in part probably due to isoform-speci®c localization, however, more study is required to clarify this discrepancy. An additional unresolved question is how 14-3-3 expression alternates with development and dierentiation.
An intriguing mechanism for 14-3-3 regulation, proposed recently, raises the possibility that the 14-3-3 proteins, despite their high level of expression in the cell, may be at limiting amounts and that revised distribution of its association with dierent targets can serve as one regulatory mechanism to modulate 14-3-3 availability (Tzivion et al., 2000) . This report suggests that induction of 14-3-3 association with intermediate ®laments such as vimentin and keratin K18 can serve to sequester 14-3-3 proteins and limit their availability to other target proteins and thereby modulate their function. This concept has been demonstrated by the ability of vimentin, when phosphorylated, to sequester 14-3-3 and restrain Raf activity. In as much as vimentin and keratins are phosphorylated during cell cycle progression and keratin K18 binds 14-3-3 in a cell cycle dependent manner (Liao and Omary, 1996) , it is proposed that intermediate ®laments may sequester 14-3-3 during cell cycle progression and disrupt other 14-3-3 target protein complexes as 14-3-3-Cdc25, thus promoting the cell cycle-dependent Cdc25 nuclear translocation and its function (Figure 3 ). However, whether this proposed regulatory mechanism is being utilized under physiological conditions awaits further con®rmation.
Conclusions and perspectives
The 14-3-3 proteins have gained much attention for the past 7 ± 8 years due to their role in the regulation of central signaling proteins. Although close to 70 proteins have already been reported to associate with 14-3-3, this list probably represents only a portion of Figure 3 A model for the role of 14-3-3-intermediate ®lament complex formation in cell cycle regulation. In resting cells 14-3-3 binding sequesters Cdc25 in the cytoplasm through its enhanced nuclear export and attenuated nuclear import. Phosphorylation of intermediate ®laments (IF) as vimentin and keratin during cell cycle progression induces their binding to 14-3-3 and to ®lament disassembly. The highly abundant IF proteins compete for 14-3-3 binding and limit its availability to other target proteins. In the absence of 14-3-3, Cdc25 accumulates in the nucleus and promotes cell cycle progression by dephosphorylating and activating Cdc2 the physiological 14-3-3 associated proteins since most of these interactors have been identi®ed in yeast-two hybrid screens in studies aimed to identify interactors for a protein of interest. Up to now no study has focused on identifying the physiological 14-3-3 interactors in vivo, thus it is not clear what fraction of the physiological 14-3-3 targets the reported 14-3-3 interactors represent. Moreover, for many of the known 14-3-3 interactors the role of 14-3-3 in the target protein regulation is not de®ned nor the kinase that mediates the binding is identi®ed. Hence, these questions need to be addressed to fully understand the regulatory mechanism whereby 14-3-3 regulates its targets. The complexity of 14-3-3 function, evident with several target proteins, suggests that as with other targets the mode of 14-3-3 action may be complex and involve several layers of regulatory mechanisms, as in the case of Raf and DAF-16 regulation. Finally, elucidation of 14-3-3 regulation itself, measurement of its availability under varying physiological conditions and studying the composition of the dierent 14-3-3 homo-and hetero-dimers may be required to elucidate how 14-3-3 proteins participate in the regulation of particular cellular processes.
